Literature DB >> 19429463

The beta3-adrenoceptor as a therapeutic target: current perspectives.

Maria Grazia Ursino1, Valentina Vasina, Emanuel Raschi, Francesca Crema, Fabrizio De Ponti.   

Abstract

beta(3)-Adrenoceptors (beta(3)-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium. They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues. The aim of this review is to highlight the functional role of beta(3)-ARs as well as to discuss their potential for drug development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429463     DOI: 10.1016/j.phrs.2009.01.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  44 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 2.  Brown adipose tissue--a new role in humans?

Authors:  Martin E Lidell; Sven Enerbäck
Journal:  Nat Rev Endocrinol       Date:  2010-04-13       Impact factor: 43.330

Review 3.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

4.  Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.

Authors:  Aaron M Cypess; Lauren S Weiner; Carla Roberts-Toler; Elisa Franquet Elía; Skyler H Kessler; Peter A Kahn; Jeffrey English; Kelly Chatman; Sunia A Trauger; Alessandro Doria; Gerald M Kolodny
Journal:  Cell Metab       Date:  2015-01-06       Impact factor: 27.287

5.  Challenges in β(3)-Adrenoceptor Agonist Drug Development.

Authors:  Jonathan R S Arch
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

6.  Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice.

Authors:  Lei Hao; Sheyenne Scott; Mehrnaz Abbasi; Yujiao Zu; Md Shahjalal Hossain Khan; Yang Yang; Dayong Wu; Ling Zhao; Shu Wang
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

7.  The action of p-synephrine on hepatic carbohydrate metabolism and respiration occurs via both Ca(2+)-mobilization and cAMP production.

Authors:  Andrea Luiza de Oliveira; Jurandir Fernando Comar; Anacharis Babeto de Sá-Nakanishi; Rosane Marina Peralta; Adelar Bracht
Journal:  Mol Cell Biochem       Date:  2013-11-28       Impact factor: 3.396

8.  (11)C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion.

Authors:  Carmelo Quarta; Filippo Lodi; Roberta Mazza; Ferdinando Giannone; Laura Boschi; Cristina Nanni; Enzo Nisoli; Stefano Boschi; Renato Pasquali; Stefano Fanti; Patricia Iozzo; Uberto Pagotto
Journal:  Mol Metab       Date:  2013-04-21       Impact factor: 7.422

9.  PDE3 and PDE4 isozyme-selective inhibitors are both required for synergistic activation of brown adipose tissue.

Authors:  Stephen M Kraynik; Robert S Miyaoka; Joseph A Beavo
Journal:  Mol Pharmacol       Date:  2013-03-14       Impact factor: 4.436

10.  New insights into molecular targets for urinary incontinence.

Authors:  Manoj K Poonia; Ginpreet Kaur; Meena Chintamaneni; Ilesh Changela
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.